[{"id":"164a11b6-0a88-4e66-b764-a14af3e3880e","acronym":"NCI-2018-01054","url":"https://clinicaltrials.gov/study/NCT03360721","created_at":"2021-01-18T16:35:16.869Z","updated_at":"2025-02-25T12:26:48.752Z","phase":"Phase 2","brief_title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03360721 - NCI-2018-01054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" AR overexpression • AR expression • AR-V7 expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR overexpression • AR expression • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-24"},{"id":"0d7ff3cc-6422-42b2-8b6f-d9a6554297bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03123978","created_at":"2021-07-07T15:54:06.603Z","updated_at":"2024-07-02T16:35:49.518Z","phase":"Phase 1","brief_title":"Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT03123978","lead_sponsor":"Mamta Parikh","biomarkers":" AR","pipe":" | ","alterations":" AR expression • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • niclosamide"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/09/2017","start_date":" 01/09/2017","primary_txt":" Primary completion: 01/14/2022","primary_completion_date":" 01/14/2022","study_txt":" Completion: 04/19/2022","study_completion_date":" 04/19/2022","last_update_posted":"2023-04-26"},{"id":"9afa8d89-1ac9-4a2d-81e2-452735aa78c1","acronym":"CABA-V7","url":"https://clinicaltrials.gov/study/NCT03050866","created_at":"2021-08-20T20:55:35.989Z","updated_at":"2024-07-02T16:36:26.076Z","phase":"Phase 2","brief_title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)","source_id_and_acronym":"NCT03050866 - CABA-V7","lead_sponsor":"Erasmus Medical Center","biomarkers":" AR","pipe":" | ","alterations":" AR-V7 expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • cabazitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/21/2017","start_date":" 02/21/2017","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 08/19/2022","study_completion_date":" 08/19/2022","last_update_posted":"2021-08-20"},{"id":"d865a9f7-2178-4ced-881c-a75158e29a4f","acronym":"PROSENZA","url":"https://clinicaltrials.gov/study/NCT02922218","created_at":"2021-01-18T14:20:52.861Z","updated_at":"2024-07-02T16:36:50.930Z","phase":"","brief_title":"PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.","source_id_and_acronym":"NCT02922218 - PROSENZA","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" PTEN • AR • ERG","pipe":" | ","alterations":" AR amplification • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression","tags":["PTEN • AR • ERG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR amplification • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Unknown status","enrollment":" Enrollment 187","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-01-27"},{"id":"4a5ef320-f912-4490-8737-c7482457db3c","acronym":"CARVE","url":"https://clinicaltrials.gov/study/NCT02621190","created_at":"2021-07-07T15:53:53.162Z","updated_at":"2024-07-02T16:37:29.724Z","phase":"Phase 2","brief_title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs","source_id_and_acronym":"NCT02621190 - CARVE","lead_sponsor":"Erasmus Medical Center","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7 • AR-V7 expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7 • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • cabazitaxel"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2016-08-17"}]